Payment overview · 2025
General Payments
$1,310.42
79 reported records · 22 companies
Healthcare provider profile · identity verified
Peter Matthew Sylves, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BUTLER, PA · NPI 1952350407
Verified facts
What the public records show
CMS Open Payments records show Peter Matthew Sylves, D.O. received $1,310.42 in general payments during 2025 across 79 reported records.
Novo Nordisk Inc accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.83 | 15.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.29 | 15.2% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.21 | 11.2% | 13 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $97.92 | 7.5% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $86.16 | 6.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.07 | 6.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.70 | 4.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.42 | 4.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.37 | 3.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $47.57 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.57 | 3.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.95 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.37 | 2.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.17 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.91 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.84 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.25 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.05 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.47 | 1.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.44 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.50 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,310.42 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $185.77 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $173.94 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $146.21 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.10 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.81 | 6 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $97.92 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $86.16 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.59 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $78.07 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.70 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $47.57 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 525 | 144 |
| Lisinopril | Lisinopril | 468 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 446 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 114 |
| Omeprazole | Omeprazole | 360 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 79 |
| Gabapentin | Gabapentin | 297 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 82 |
| Metformin Hcl | Metformin Hcl | 238 | 63 |
| Furosemide | Furosemide | 212 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 51 |
| Potassium Chloride | Potassium Chloride | 202 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 49 |
| Valsartan | Valsartan | 167 | 32 |
| Celecoxib | Celecoxib | 163 | 39 |
| Losartan Potassium | Losartan Potassium | 162 | 50 |
| Metformin Hcl Er | Metformin Hcl | 158 | 41 |
| Jardiance | Empagliflozin | 155 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 44 |
| Allopurinol | Allopurinol | 140 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 54 |
| Alendronate Sodium | Alendronate Sodium | 137 | 29 |
| Simvastatin | Simvastatin | 132 | 41 |
| Atenolol | Atenolol | 130 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 34 |
| Eliquis | Apixaban | 123 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 38 |
| Lorazepam | Lorazepam | 119 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 27 |
| Ozempic | Semaglutide | 111 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 22 |
| Farxiga | Dapagliflozin Propanediol | 100 | 18 |
| Prednisone | Prednisone | 94 | 55 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Trazodone Hcl | Trazodone Hcl | 89 | 24 |
| Methylprednisolone | Methylprednisolone | 87 | 66 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 21 |
| Clonazepam | Clonazepam | 81 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 19 |
| Tramadol Hcl | Tramadol Hcl | 77 | 20 |
| Irbesartan | Irbesartan | 75 | 18 |
| Carvedilol | Carvedilol | 74 | 21 |
| Meloxicam | Meloxicam | 70 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 20 |
| Repaglinide | Repaglinide | 66 | 16 |
| Enalapril Maleate | Enalapril Maleate | 65 | 13 |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 15 |
| Ezetimibe | Ezetimibe | 56 | 18 |
| Bumetanide | Bumetanide | 52 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Baclofen | Baclofen | 51 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 16 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Finasteride | Finasteride | 45 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 11 |
| Famotidine | Famotidine | 43 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Methocarbamol | Methocarbamol | 38 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,310.42 · 79 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, M-M-R II, MOUNJARO, ONZETRA XSAIL, OTEZLA, Ozempic, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error